106 related articles for article (PubMed ID: 10691206)
1. Comparative in vitro activity of quinolones against Stenotrophomonas maltophilia.
Valdezate S; Vindel A; Baquero F; Cantón R
Eur J Clin Microbiol Infect Dis; 1999 Dec; 18(12):908-11. PubMed ID: 10691206
[TBL] [Abstract][Full Text] [Related]
2. In vitro activity of clinafloxacin in comparison with other quinolones against Stenotrophomonas maltophilia clinical isolates in the presence and absence of reserpine.
Ribera A; Jurado A; Ruiz J; Marco F; Del Valle O; Mensa J; Chaves J; Hernández G; Jiménez de Anta MT; Vila J
Diagn Microbiol Infect Dis; 2002 Feb; 42(2):123-8. PubMed ID: 11858908
[TBL] [Abstract][Full Text] [Related]
3. Comparative activity of new quinolones against 326 clinical isolates of Stenotrophomonas maltophilia.
Weiss K; Restieri C; De Carolis E; Laverdière M; Guay H
J Antimicrob Chemother; 2000 Mar; 45(3):363-5. PubMed ID: 10702558
[TBL] [Abstract][Full Text] [Related]
4. Resistance of Stenotrophomonas maltophilia to Fluoroquinolones: Prevalence in a University Hospital and Possible Mechanisms.
Jia W; Wang J; Xu H; Li G
Int J Environ Res Public Health; 2015 May; 12(5):5177-95. PubMed ID: 25985315
[TBL] [Abstract][Full Text] [Related]
5. Antimicrobial susceptibility profile of molecular typed cystic fibrosis Stenotrophomonas maltophilia isolates and differences with noncystic fibrosis isolates.
Cantón R; Valdezate S; Vindel A; Sánchez Del Saz B; Maíz L; Baquero F
Pediatr Pulmonol; 2003 Feb; 35(2):99-107. PubMed ID: 12526070
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of moxifloxacin against Stenotrophomonas maltophilia blood isolates from patients with hematologic malignancies.
Venditti M; Monaco M; Micozzi A; Tarasi A; Friedrich A; Martino P
Clin Microbiol Infect; 2001 Jan; 7(1):37-9. PubMed ID: 11284945
[No Abstract] [Full Text] [Related]
7. Comparative in vitro activity of levofloxacin and ciprofloxacin against bacterial isolates from neutropenic patients.
Di Bonaventura G; D'Antonio D; Catamo G; D'Ercole S; Piccolomini R
Chemotherapy; 2002 Jul; 48(3):134-7. PubMed ID: 12138329
[TBL] [Abstract][Full Text] [Related]
8. [Molecular epidemiology of Stenotrophomonas maltophilia strains isolated from paediatric patients].
Köseoğlu O; Sener B; Gür D
Mikrobiyol Bul; 2004; 38(1-2):9-19. PubMed ID: 15293897
[TBL] [Abstract][Full Text] [Related]
9. Antimicrobial susceptibility profile of contemporary clinical strains of Stenotrophomonas maltophilia isolates: can moxifloxacin activity be predicted by levofloxacin MIC results?
Galles AC; Jones RN; Sader HS
J Chemother; 2008 Feb; 20(1):38-42. PubMed ID: 18343741
[TBL] [Abstract][Full Text] [Related]
10. Activity of levofloxacin and ciprofloxacin on biofilms and planktonic cells of Stenotrophomonas maltophilia isolates from patients with device-associated infections.
Passerini de Rossi B; García C; Calenda M; Vay C; Franco M
Int J Antimicrob Agents; 2009 Sep; 34(3):260-4. PubMed ID: 19362452
[TBL] [Abstract][Full Text] [Related]
11. Antimicrobial susceptibility of stenotrophomonas maltophilia isolates from Korea, and the activity of antimicrobial combinations against the isolates.
Chung HS; Hong SG; Kim YR; Shin KS; Whang DH; Ahn JY; Park YJ; Uh Y; Chang CL; Shin JH; Lee HS; Lee K; Chong Y
J Korean Med Sci; 2013 Jan; 28(1):62-6. PubMed ID: 23341713
[TBL] [Abstract][Full Text] [Related]
12. Mutations in gyrA and parC QRDRs are not relevant for quinolone resistance in epidemiological unrelated Stenotrophomonas maltophilia clinical isolates.
Ribera A; Doménech-Sanchez A; Ruiz J; Benedi VJ; Jimenez de Anta MT; Vila J
Microb Drug Resist; 2002; 8(4):245-51. PubMed ID: 12523620
[TBL] [Abstract][Full Text] [Related]
13. In vitro activity of eight fluoroquinolones against multiresistant Stenotrophomonas maltophilia.
Sánchez-Hernández J; Manzanares MA; Gutiérrez Zufiaurre MN; Muñoz Criado S; Muñoz Bellido JL; García-Rodríguez JA
Rev Esp Quimioter; 1999 Sep; 12(3):234-6. PubMed ID: 10878514
[TBL] [Abstract][Full Text] [Related]
14. Antimicrobial activities of gatifloxacin against nosocomial isolates of Stenotrophomonas maltophilia measured by MIC and time-kill studies.
Cohn ML; Waites KB
Antimicrob Agents Chemother; 2001 Jul; 45(7):2126-8. PubMed ID: 11408235
[TBL] [Abstract][Full Text] [Related]
15. Infection and colonization by Stenotrophomonas maltophilia: antimicrobial susceptibility and clinical background of strains isolated at a tertiary care centre in Hungary.
Juhász E; Krizsán G; Lengyel G; Grósz G; Pongrácz J; Kristóf K
Ann Clin Microbiol Antimicrob; 2014 Dec; 13():333. PubMed ID: 25551459
[TBL] [Abstract][Full Text] [Related]
16. Levofloxacin in vitro activity and time-kill evaluation of Stenotrophomonas maltophilia clinical isolates.
Bonfiglio G; Cascone C; Azzarelli C; Cafiso V; Marchetti F; Stefani S
J Antimicrob Chemother; 2000 Jan; 45(1):115-7. PubMed ID: 10629022
[TBL] [Abstract][Full Text] [Related]
17. Antimicrobial susceptibilities of a worldwide collection of Stenotrophomonas maltophilia isolates tested against tigecycline and agents commonly used for S. maltophilia infections.
Farrell DJ; Sader HS; Jones RN
Antimicrob Agents Chemother; 2010 Jun; 54(6):2735-7. PubMed ID: 20368399
[TBL] [Abstract][Full Text] [Related]
18. In vitro susceptibility of Stenotrophomonas maltophilia isolates: comparison of disc diffusion, Etest and agar dilution methods.
Nicodemo AC; Araujo MR; Ruiz AS; Gales AC
J Antimicrob Chemother; 2004 Apr; 53(4):604-8. PubMed ID: 14973153
[TBL] [Abstract][Full Text] [Related]
19. In-vitro activity of trovafloxacin against clinical bacterial isolates from patients with cancer.
Rolston KV; Ho DH; LeBlanc B; Streeter H; Dvorak T
J Antimicrob Chemother; 1997 Jun; 39 Suppl B():15-22. PubMed ID: 9222065
[TBL] [Abstract][Full Text] [Related]
20. [Accumulation and efflux of quinolones by clinical isolates of Stenotrophomonas maltophilia].
Sánchez P; Alonso A; Campanario E; Alós I; Martíinez JL
Rev Esp Quimioter; 2000 Jun; 13(2):176-81. PubMed ID: 10918091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
